JTWM
NBIX icon

Jackson Thornton Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Jackson Thornton Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Sell
2,633
-627
-19% -$93K 0.04% 169
2026
Q1 		$420K Sell
3,260
-248
-7% -$32.9K 0.04% 128
2025
Q4 		$482K Buy
3,508
+137
+4% +$19.8K 0.05% 116
2025
Q3 		$469K Buy
+3,371
New +$457K 0.05% 107

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jackson Thornton Wealth Management's NBIX Position: Q2 2026 in Review

Jackson Thornton Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, selling an estimated $93K and leaving 2,633 shares worth $444K. The position accounts for 0.04% of the portfolio, ranked #169.

Jackson Thornton Wealth Management first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $482K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Jackson Thornton Wealth Management held 2,633 shares of Neurocrine Biosciences worth $444K as of Q2 2026.
  • Jackson Thornton Wealth Management sold 627 Neurocrine Biosciences shares in Q2 2026, an estimated $93K.
  • Neurocrine Biosciences made up 0.04% of Jackson Thornton Wealth Management's portfolio in Q2 2026, its #169 holding.
  • Jackson Thornton Wealth Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Jackson Thornton Wealth Management's Neurocrine Biosciences position peaked at $482K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.